Serum Uromodulin Levels Reflect Severity of Clinicopathological Findings in Early Stage IgA Nephropathy

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Access via DeepDyve Unlimited fulltext viewing Of this article Organize, annotate And mark up articles Printing And downloading restrictions apply

Select

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Abstract of Novel Research Findings

Received: May 13, 2022
Accepted: June 24, 2022
Published online: August 03, 2022

Number of Print Pages: 11
Number of Figures: 3
Number of Tables: 6

ISSN: 0250-8095 (Print)
eISSN: 1421-9670 (Online)

For additional information: https://www.karger.com/AJN

Abstract

Introduction: Uromodulin (UMOD), also known as Tamm-Horsfall protein, is a kidney-specific protein. Recently, low levels of urinary UMOD (uUMOD) have been reported as a risk factor for renal function decline in IgA nephropathy (IgAN). However, the clinical significance of serum UMOD (sUMOD) is not clear. In this study, we clarified the clinical significance of sUMOD in IgAN. Methods: One hundred eight biopsy-proven IgAN patients were included in this study. The relationships between sUMOD levels and various clinicopathological findings were evaluated. Results: sUMOD was positively correlated with estimated glomerular filtration rate (eGFR) (p < 0.001, r = 0.5) and negatively correlated with creatinine (Cr) (p < 0.0001, r = −0.51) and urinary protein (UP) (p = 0.005, r = −0.33). In the low sUMOD group (<145 ng/mL), Cr was significantly higher (p < 0.0001) and histopathological changes were severe. The cumulative incidence of a 30% decline in eGFR was 25.6% overall, 0% in histological grade (H-G) I, 33.3% in H-G II, 59.6% in H-G III, and 66.7% in H-G IV. In univariate analyses, prognostic factors for a 30% decline in eGFR were male, high UP, low albumin, low eGFR, and low sUMOD. When comparing the severe histopathological classes (H-G II–IV) and H-G I, low sUMOD was a risk factor for severe histopathological changes. Furthermore, in patients with eGFR > 60 (n = 74), multivariate analyses revealed that low sUMOD independently predicted a 30% decline in eGFR and having severe histopathological changes. Conclusion: In IgAN, sUMOD levels were associated with renal function. Low sUMOD levels may be a risk factor for worsening renal function, especially in the early stage of IgAN.

© 2022 S. Karger AG, Basel

References Tamm I, Horsfall FL Jr. Characterization and separation of an inhibitor of viral hemagglutination present in urine. Proc Soc Exp Biol Med. 1950;74(1):108–14. Tamm I, Horsfall FL Jr. A mucoprotein derived from human urine which reacts with influenza, mumps, and Newcastle disease viruses. J Exp Med. 1952;95(1):71–97. Muchmore AV, Decker JM. Uromodulin: a unique 85-kilodalton immunosuppressive glycoprotein isolated from urine of pregnant women. Science. 1985;229(4712):479–81. Pennica D, Kohr WJ, Kuang WJ, Glaister D, Aggarwal BB, Chen EY, et al. Identification of human uromodulin as the Tamm-Horsfall urinary glycoprotein. Science. 1987;236(4797):83–8. Köttgen A, Glazer NL, Dehghan A, Hwang SJ, Katz R, Li M, et al. Multiple loci associated with indices of renal function and chronic kidney disease. Nat Genet. 2009;41(6):712–7. Devuyst O, Bochud M. Uromodulin, kidney function, cardiovascular disease, and mortality. Kidney Int. 2015;88(5):944–6. Delgado GE, Kleber ME, Scharnagl H, Krämer BK, März W, Scherberich JE, et al. Serum uromodulin and mortality risk in patients undergoing coronary angiography. J Am Soc Nephrol. 2017;28(7):2201–10. Steubl D, Schneider MP, Meiselbach H, Nadal J, Schmid MC, Saritas T, et al. Association of serum uromodulin with death, cardiovascular events, and kidney failure in CKD. Clin J Am Soc Nephrol. 2020;15(5):616–24. Scherberich JE, Gruber R, Nockher WA, Christensen EI, Schmitt H, Herbst V, et al. Serum uromodulin: a marker of kidney function and renal parenchymal integrity. Nephrol Dial Transplant. 2018;33(2):284–95. Kuśnierz-Cabala B, Gala-Błądzińska A, Mazur-Laskowska M, Dumnicka P, Sporek M, Matuszyk A, et al. Serum uromodulin levels in prediction of acute kidney injury in the early phase of acute pancreatitis. Molecules. 2017;22(6):988. Tachibana S, Iyoda M, Suzuki T, Kanazawa N, Iseri K, Wada Y, et al. Serum uromodulin is associated with the severity of clinicopathological findings in ANCA-associated glomerulonephritis. PLoS One. 2019;14(11):e0224690. Clinical guides for immunoglobulin A (IgA) nephropathy in Japan, third version. Nihon Jinzo Gakkai Shi. 2011;53(2):123–35. Yuzawa Y, Yamamoto R, Takahashi K, Katafuchi R, Tomita M, Fujigaki Y, et al. Evidence-based clinical practice guidelines for IgA nephropathy 2014. Clin Exp Nephrol. 2016;20(4):511–35. Cattran DC, Coppo R, Cook HT, Feehally J, Roberts IS, Troyanov S, et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009;76(5):534–45. Zhou J, Chen Y, Liu Y, Shi S, Wang S, Li X, et al. Urinary uromodulin excretion predicts progression of chronic kidney disease resulting from IgA nephropathy. PLoS One. 2013;8(8):e71023. Shen F, Liu M, Pei F, Yu L, Yang X. Role of uromodulin and complement activation in the progression of kidney disease. Oncol Lett. 2021;22(6):829. Usui R, Ogawa T, Takahashi H, Iwasaki C, Koike M, Morito T, et al. Serum uromodulin is a novel renal function marker in the Japanese population. Clin Exp Nephrol. 2021;25(1):28–36. Serafini-Cessi F, Malagolini N, Cavallone D. Tamm-Horsfall glycoprotein: biology and clinical relevance. Am J Kidney Dis. 2003;42(4):658–76. Wangsiripaisan A, Gengaro PE, Edelstein CL, Schrier RW. Role of polymeric Tamm-Horsfall protein in cast formation: oligosaccharide and tubular fluid ions. Kidney Int. 2001;59(3):932–40. Duncan JL. Differential effect of Tamm-Horsfall protein on adherence of Escherichia coli to transitional epithelial cells. J Infect Dis. 1988;158(6):1379–82. Nie M, Bal MS, Liu J, Yang Z, Rivera C, Wu XR, et al. Uromodulin regulates renal magnesium homeostasis through the ion channel transient receptor potential melastatin 6 (TRPM6). J Biol Chem. 2018;293(42):16488–502. Wolf MT, Wu XR, Huang CL. Uromodulin upregulates TRPV5 by impairing caveolin-mediated endocytosis. Kidney Int. 2013;84(1):130–7. Renigunta A, Renigunta V, Saritas T, Decher N, Mutig K, Waldegger S, et al. Tamm-Horsfall glycoprotein interacts with renal outer medullary potassium channel ROMK2 and regulates its function. J Biol Chem. 2011;286(3):2224–35. Mutig K, Kahl T, Saritas T, Godes M, Persson P, Bates J, et al. Activation of the bumetanide-sensitive Na+, K+, 2Cl− cotransporter (NKCC2) is facilitated by Tamm-Horsfall protein in a chloride-sensitive manner. J Biol Chem. 2011;286(34):30200–10. Säemann MD, Weichhart T, Hörl WH, Zlabinger GJ. Tamm-Horsfall protein: a multilayered defence molecule against urinary tract infection. Eur J Clin Invest. 2005;35(4):227–35. Weichhart T, Zlabinger GJ, Säemann MD. The multiple functions of Tamm-Horsfall protein in human health and disease: a mystery clears up. Wien Klin Wochenschr. 2005;117(9–10):316–22. El-Achkar TM, Wu XR, Rauchman M, McCracken R, Kiefer S, Dagher PC, et al. Tamm-Horsfall protein protects the kidney from ischemic injury by decreasing inflammation and altering TLR4 expression. Am J Physiol Renal Physiol. 2008;295(2):F534–44. Rhodes DC, Hinsman EJ, Rhodes JA. Tamm-Horsfall glycoprotein binds IgG with high affinity. Kidney Int. 1993;44(5):1014–21. Rhodes DC. Binding of Tamm-Horsfall protein to complement 1q and complement 1, including influence of hydrogen-ion concentration. Immunol Cell Biol. 2002;80(6):558–66. Su SJ, Chang KL, Lin TM, Huang YH, Yeh TM. Uromodulin and Tamm-Horsfall protein induce human monocytes to secrete TNF and express tissue factor. J Immunol. 1997;158(7):3449–56. Schmid M, Prajczer S, Gruber LN, Bertocchi C, Gandini R, Pfaller W, et al. Uromodulin facilitates neutrophil migration across renal epithelial monolayers. Cell Physiol Biochem. 2010;26(3):311–8. Hession C, Decker JM, Sherblom AP, Kumar S, Yue CC, Mattaliano RJ, et al. Uromodulin (Tamm-Horsfall glycoprotein): a renal ligand for lymphokines. Science. 1987;237(4821):1479–84. Levey AS, Gansevoort RT, Coresh J, Inker LA, Heerspink HL, Grams ME, et al. Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency. Am J Kidney Dis. 2020;75(1):84–104. Article / Publication Details

First-Page Preview

Abstract of Novel Research Findings

Received: May 13, 2022
Accepted: June 24, 2022
Published online: August 03, 2022

Number of Print Pages: 11
Number of Figures: 3
Number of Tables: 6

ISSN: 0250-8095 (Print)
eISSN: 1421-9670 (Online)

For additional information: https://www.karger.com/AJN

留言 (0)

沒有登入
gif